Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease

Bone Marrow Transplantation

Volumn 40, Issue 5, 2007, Pages 481-486

  Perales, M A ^a   Ishill, N ^a   Lomazow, W A ^a   Weinstock, D M ^a   Papadopoulos, E B ^a   Dastigir, H ^a   Chiu, M ^a   Boulad, F ^a   Castro Malaspina, H R ^a   Heller, G ^a   Jakubowski, A A ^a   O'Reilly, R J ^a   Small, T N ^a   Young, J W ^a   Kernan, N A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOSPORIN; DACLIZUMAB; METHOTREXATE; METHYLPREDNISOLONE; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; DEATH; FEMALE; FOLLOW UP; HUMAN; INFANT; LEUKEMIA; LONG TERM CARE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MYCOSIS; MYELODYSPLASTIC SYNDROME; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; DRUG EVALUATION; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; RETROSPECTIVE STUDIES; STEROIDS; TRANSPLANTATION, HOMOLOGOUS;

EID: 34548062133     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705762     Document Type: Review

References (25)

1. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs-host disease. Biol Blood Marrow Transplant 1999; 5: 347-356.
2. van den Brink MR, Burakoff SJ. Cytolytic pathways in haematopoietic stem-cell transplantation. Nat Rev Immunol 2002; 2: 273-281.
3. Waldmann TA. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 1986; 232: 727-732.
4. Takeshita T, Asao H, Ohtani K, Ishii N, Kumaki S, Tanaka N et al. Cloning of the gamma chain of the human IL-2 receptor. Science 1992; 257: 379-382.
5. Uchiyama T, Broder S, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol 1981; 126: 1393-1397.
6. Uchiyama T, Nelson DL, Fleisher TA, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells. J Immunol 1981; 126: 1398-1403.
7. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989; 86: 10029-10033.
8. Junghans RP, Waldmann TA, Landolfi NF, Avdalovic NM, Schneider WP, Queen C. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 1990; 50: 1495-1502.
9. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338: 161-165.
10. Anasetti C, Hansen JA, Waldmann TA, Appelbaum FR, Davis J, Deeg HJ et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: An antibody that binds to the interleukin-2 receptor. Blood 1994; 84: 1320-1327.
11. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt, S, Khouri I et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95: 83-89.
12. Willenbacher W, Basara N, Blau IW, Fauser AA, Kiehl MG. Treatment of steroid refractory acute and chronic graft-versushost disease with daclizumab. Br J Haematol 2001; 112: 820-823.
13. Srinivasan R, Chakrabarti S, Walsh T, Igarashi T, Takahashi Y, Kleiner D et al. Improved surviyal in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004; 124: 777-786.
14. Teachey DT, Bickert B, Bunin N. Daclizumab for children with corticosteroid refractory graft-versus-host disease. Bone Marrow Transplant 2006; 37: 95-99.
15. Wagner JE, Thomoson JS, Carter SL, Kernan NA. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): A multi-centre, randomised phase II-III trial. Lancet 2005; 366 733-741.
16. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
17. Arai S, Margolis J, Zahurak M, Anders V, Vogelsang GB. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002; 8: 155-160.
18. McCaul KG, Nevill TJ, Barnett MJ, Toze CL, Currie CJ, Sutherland HJ et al. Treatment of steroid-resistant acute graftversus-host disease with rabbit antithymocyte globulin. J Hematother Stem Cell Res 2000; 9: 367-374.
19. Remberger M, Ringden O, Aschan J, Ljungman P, Lonnqvist B, Markling L. Long-term follow-up of a randomized trial comparing T-cell depletion with a combination of methotrexate and cyclosporine in adult leukemic marrow transplant recipients. Transplant Proc 1994; 26: 1829-1830.
20. Khoury H, Kashyap A, Adkins DR, Brown RA, Miller G, Vij R et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 2001; 27: 1059-1064.
21. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: A meta-analysis of randomized trials. Transplantation 2004; 77: 166-176.
22. Blaise D, Olive D, Michallet M, Marit G, Leblond V, Maraninchi D. Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graftversus-host prophylaxis. Lancet 1995; 345: 1144-1146.
23. Belanger C, Esperou-Bourdeau H, Bordigoni P, Jouet JP, Souillet G, Milpied N et al. Use of an anti-interleukin-2 receptor monoclonal antibody for GVHD prophylaxis in unrelated donor BMT. Bone Marrow Transplant 1993; 11: 293-297.
24. Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy Jr PL et al. Effect of up-front daclihzumab when combined with steroids for the treatment of acute graft-versushost disease: Results of a randomized trial. Blood 2004; 104: 1559-1564.
25. Cragg L, Blazar BR, Defor T, Kolatker N, Miller W, Kersey J et al. A randomized trial comparing prednisone with antithymocyte globulin/ prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 2000; 6 441-447.